Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy.

BACKGROUND Sporadic primary hyperparathyroidism (PHPT) occurs most frequently in postmenopausal women. Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal-dominant disease in which mild to moderate PHPT develops in most gene carriers by 20 years of age. Primary hyperparathyroidism associated with MEN 1 is typically recurrent, despite initially successful subtotal parathyroidectomy. Osteoporosis is considered a complication of sporadic PHPT and an indication for parathyroidectomy. In the setting of MEN 1, however, the relationship of bone mass to PHPT, fracture risk, and parathyroidectomy is unknown. HYPOTHESIS Parathyroidectomy improves bone mineral density for patients with primary hyperparathyroidism in the setting of MEN 1. DESIGN Case series. SETTING Tertiary referral center. PATIENTS Twenty-nine women with MEN 1 belonging to a single family with a history of MEN 1. INTERVENTIONS Parathyroidectomy. MAIN OUTCOME MEASURES Bone mineral density (BMD) and history of skeletal fracture. RESULTS Osteopenia and osteoporosis were diagnosed in 41% and 45% of patients, respectively. Forty-four percent of patients with uncontrolled PHPT had severe osteopenia (T score, <-2.0) by 35 years of age. Reduction in BMD was greatest at the femoral neck. Reduced BMD was associated with an increased likelihood of skeletal fracture (P = .05). Patients with uncontrolled PHPT had lower femoral neck and lumbar spine BMDs than those in whom PHPT was controlled by parathyroidectomy (P = .005 and .02, respectively). Successful parathyroidectomy improved femoral neck and lumbar spine BMDs by a mean +/- SEM of 5.2% +/- 2.5% and 3.2% +/- 2.9%, respectively. CONCLUSIONS Osteoporosis is a frequent and early complication of PHPT in MEN 1. Despite difficulty in achieving a cure of PHPT in MEN 1, parathyroidectomy has an important role in the optimization of BMD for patients with MEN 1.

[1]  N. Watts Treatment of osteoporosis with bisphosphonates. , 2001, Rheumatic diseases clinics of North America.

[2]  J. Burgess,et al.  Enteropancreatic malignancy associated with multiple endocrine neoplasia type 1 , 1998, Cancer.

[3]  Burgess,et al.  Expression of the MEN‐1 gene in a large kindred with multiple endocrine neoplasia type 1 , 1998, Journal of internal medicine.

[4]  P. Ross Risk factors for osteoporotic fracture. , 1998, Endocrinology and metabolism clinics of North America.

[5]  I. Reid The roles of calcium and vitamin D in the prevention of osteoporosis. , 1998, Endocrinology and metabolism clinics of North America.

[6]  R. Lindsay The role of estrogen in the prevention of osteoporosis. , 1998, Endocrinology and metabolism clinics of North America.

[7]  S. Silverberg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Treatment of Hypercalcemia Secondary to Parathyroid Carcinoma with a Novel Calcimimetic Agent , 1997 .

[8]  J. Burgess,et al.  The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. , 1998, Archives of surgery.

[9]  E. Thurfjell,et al.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. , 1997, Surgery.

[10]  S. Silverberg,et al.  Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. , 1996, The Journal of clinical endocrinology and metabolism.

[11]  N. Thompson The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient , 1995, Journal of internal medicine.

[12]  E. Siris,et al.  Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[13]  J. Rastad,et al.  Multiple endocrine neoplasia type 1. Clinical features and screening. , 1994, Endocrinology and metabolism clinics of North America.

[14]  L. Mallette Management of hyperparathyroidism in the multiple endocrine neoplasia syndromes and other familial endocrinopathies. , 1994, Endocrinology and metabolism clinics of North America.

[15]  E. Romagnoli,et al.  Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover. , 1993, Bone and mineral.

[16]  J. Valvanne,et al.  Serum ionized calcium and the prevalence of primary hyperparathyroidism in age cohorts of 75, 80 and 85 years , 1992, Journal of internal medicine.

[17]  J. Shepherd The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? , 1991, Archives of surgery.

[18]  J. Nordenström,et al.  Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. , 1990, Surgery.

[19]  T. Clemens,et al.  Skeletal disease in primary hyperparathyroidism , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  M. Brandi,et al.  Familial multiple endocrine neoplasia type I: a new look at pathophysiology. , 1987, Endocrine reviews.

[21]  R M Neer,et al.  Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.